Abstract
The diagnosis and management of chronic heart failure (CHF) with preserved left ventricular (LV) systolic function are problematic. Management strategies in current CHF guidelines are largely speculative, as to date few trials have studied such patients.The Candesartan in Heart Failure Assessment of Reduction in Mortality and morbidity (CHARM)-Preserved study, the only study that has specifically recruited CHF patients with preserved left ventricular ejection fraction (LVEF), provides direct evidence that treatment with candesartan has substantial clinical benefits in this patient group, and this has been recognised in current guidelines for management of CHF. This treatment strategy warrants consideration in the management of these patients in the routine clinical setting. This case report discusses some of the issues in diagnosis and management of a patient with preserved LVEF.
Get full access to this article
View all access options for this article.